Shandong Lukang Pharmaceutical wins bids in national drug procurement

Shandong Lukang Pharmaceutical Co., Ltd. and its controlled subsidiary, Shandong Lukang Pharmaceutical Group Saite Co., Ltd., announced successful bids in the eleventh round of national centralized drug procurement (GY-YD2025-1). The winning products include Ceftizoxime Sodium for Injection, Dapagliflozin Tablets, Adenosylcobalamin Capsules, and Methocarbamol Injection, covering therapeutic areas such as infections, diabetes, anemia, and musculoskeletal pain.

Sales revenue for these awarded products totaled 404.76 million yuan in 2024, representing 6.49% of the company's total operating revenue for that year. For the first half of 2025, sales revenue reached 225.2379 million yuan, accounting for 7.14% of the company's total operating revenue for the period.

This procurement participation is expected to facilitate the rapid entry of new products into the market and expand the company's coverage in relevant drug fields. While the profitability of the winning products may face adjustments, the company plans to optimize its product structure and strengthen cost control to enhance operational management quality.